Abstract
Kawasaki disease, or mucocutaneous lymph node syndrome, was first described in Japan in the late 1960s as an illness characterized by persistent fever, conjunctivitis, mucous membrane changes, acral erythema with desquamation, and cervical adenopathy, associated with coronary arteritis (1,2). While earlier descriptions of the disease were limited to Asia and Hawaii, the disease is now known to occur worldwide. The disease is primarily one of young children, with 85% of cases occurring in children under five years. It is uncommon in children less than 6 months. There have been some epidemiologic investigations linking Kawasaki disease to freshly cleaned carpets, humidifier use, and living near a body of water, but these associations have not been observed consistently (3).
Chapter PDF
Keywords
- Kawasaki Disease
- Scarlet Fever
- Coronary Aneurysm
- Coronary Magnetic Resonance Angiography
- Kawasaki Syndrome
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Kawasaki T. Mucocutaneous lymph node syndrome: Clinical observation of 50 cases. Jpn J Allerg 1967;16:178–222 (in Japanese)
Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271–276.
Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004;364:533–544.
Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005;191:499–502.
Rowley AH, Eckerly CA, Hans-Martin J, Shulman ST, Baker SC. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol 1997;159:5946–5955.
Rowley AH, Shulman ST, Spike BT, Mask CA, Baker SC. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol 2001;166:1334–1343.
Friter BS, Lucky AW. The perineal eruption of Kawasaki syndrome. Arch Dermatol 1988;124:1805–1810.
Kimura T, Miyazawa H, Watanabe K, Moriya T. Small pustules in Kawasaki disease: A clinicopathological study of four patients. Am J Dermatopathol 1988;10:218–223.
Greil GF, Stuber M, Botnar RM, et al. Coronary magnetic resonance angiography in adolescents and young adults with Kawasaki disease. Circulation 2002;105:908–911.
Barone SR, Pontrelli LR, Krilov LR. The differentiation of classic Kawasaki disease, atypical Kawasaki disease, and acute adenoviral infection: Use of clinical features and a rapid direct fluorescent antigen test. Arch Pediatr Adolesc Med 2000;154:453–456.
Jennette JC. Implications for pathogenesis patterns of injury in small-and medium-sized-vessel vasculitis. Cleveland Clin J Med 2003;69: SII-33–38.
Terai M, Yasukawa K, Honda T. Peripheral blood eosinophilia and eosinophil accumulation in coronary microvessels in acute Kawasaki disease. Pediatr Infect Dis J 2002;8:777–781.
Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341–347.
Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombotic therapy in children: The Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:645S–687S.
Brogan PA, Bose A, Burgner D, et al. Kawasaki disease: An evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child 2002;86:286–290.
Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888–893.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Treatment of Kawasaki disease: Aspirin’s role in the febrile stage revisited. Pediatrics 2004;114:689–693.
Freeman AF, Shulman ST. Refractory Kawasaki disease. Pediatr Infect Dis J 2004;23:463–464.
Miura M, Ohki H, Tsuchihashi T, et al. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin. Arch Dis Child 2004;89:776–780.
Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as novel therapy for refractory Kawasaki disease. J Rheumatol 2004;31:808–810.
Sundel RP, Baker AL, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: Report of a randomized trial. J Pediatr 2003;142:611–616.
Kato H, Sugimura T, Akagi T, et al. Long term consequences of Kawasaki disease. Circulation 1996;94:1379–1385.
Mitani Y, Sawada H, Hayakawa H, et al. Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease: Association between inflammation and late coronary sequelae in Kawasaki disease. Circulation 2005;111:38–43.
Michie C, Kinsler V, Tulloh R, Davidson S. Recurrent skin peeling following Kawasaki disease. Arch Dis Child 2000;83:353–355.
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
(2007). Kawasaki Disease. In: Deadly Dermatologic Diseases. Springer, New York, NY. https://doi.org/10.1007/978-0-387-68858-9_36
Download citation
DOI: https://doi.org/10.1007/978-0-387-68858-9_36
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-25442-5
Online ISBN: 978-0-387-68858-9
eBook Packages: MedicineMedicine (R0)